Target Price | $26.00 |
Price | $16.90 |
Potential |
53.85%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target ADMA Biologics, Inc. 2026 .
The average ADMA Biologics, Inc. target price is $26.00.
This is
53.85%
register free of charge
$28.00
65.68%
register free of charge
$25.00
47.93%
register free of charge
|
|
A rating was issued by 4 analysts: 4 Analysts recommend ADMA Biologics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ADMA Biologics, Inc. stock has an average upside potential 2026 of
53.85%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 258.22 | 421.67 |
67.59% | 63.30% | |
EBITDA Margin | 11.60% | 38.82% |
155.07% | 234.58% | |
Net Margin | -11.90% | 28.40% |
76.49% | 338.65% |
3 Analysts have issued a sales forecast ADMA Biologics, Inc. 2024 . The average ADMA Biologics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an ADMA Biologics, Inc. EBITDA forecast 2024. The average ADMA Biologics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 ADMA Biologics, Inc. Analysts have issued a net profit forecast 2024. The average ADMA Biologics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.13 | 0.51 |
60.61% | 492.31% | |
P/E | 33.36 | |
EV/Sales | 9.53 |
3 Analysts have issued a ADMA Biologics, Inc. forecast for earnings per share. The average ADMA Biologics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ADMA Biologics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
ADMA Biologics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.